Objective To evaluate the prognostic value of sequential dual-phase CBCT (DP-CBCT) imaging performed during degradable starch microsphere TACE (DSM-TACE) session in predicting the HCC's response to treatment, evaluate with modify response evaluation criteria in solid tumours (mRECIST) at 1-month multi-detector CT (MDCT) follow-up. Materials and methods Between January and May 2018, 24 patients (68.5 ± 8.5 year [45-85]) with HCC lesions (n = 96 [average 4/patient]) were prospectively enrolled. Imaging assessment included: pre-procedural MDCT, intra-procedural DP-CBCT performed before first and second DSM-TACEs and 1-month follow-up MDCT. Lesions' attenuation/pseudoattenuation was defined as average value measured on ROIs (HU for MDCT; arbitrary unit called HU* for CBCT). Lesions' attenuation modification was correlated with the post-procedural mRECIST criteria at 1-month MDCT. Results Eighty-two DSM-TACEs were performed. Lesion's attenuation values were: pre-procedural MDCT arterial phase (AP) 107.00 HU (CI 95% 100.00-115.49), venous phase (VP) 85.00 HU (CI 95% 81.13-91.74); and lesion's pseudoattenuation were: first CBCT-AP 305.00 HU* (CI 95% 259.77-354.04), CBCT-VP 155.00 HU* (CI 95% 135.00-163.34). For second CBCT were: -AP 210.00 HU* (CI 95% 179.47-228.58), -VP 141.00 HU* (CI 95% 125.47-158.11); and for postprocedural MDCT were: -AP 95.00 HU (CI 95% 81.35-102.00), -VP 83.00 HU (CI 95% 78.00-88.00). ROC curve analysis showed that a higher difference pseudo-attenuation between first and second DP-CBCTs is related to treatment response. The optimal cut-off value of the difference between first and second CBCT-APs to predict complete response, objective response (complete + partial response) and overall disease control (objective response + stable disease) were > 206 HU* (sensitivity 80.0%, specificity 81.7%), > 72 HU* (sensitivity 79.5%, specificity 83.0%) and > − 7 HU* (sensitivity 91.6%, specificity 65.4%), respectively. Conclusions DP-CBCT can predict intra-procedurally, by assessing lesion pseudo-attenuation modification, the DSM-TACE 1-month treatment outcome.
Introduction
Catheter-based treatments represent an alternative treatment for intermediate-stage hepato-cellular carcinoma (HCC) [1] . Most of treatments, especially when dealing with those with advanced-stage disease, entail multiple sessions of lobar treatments. In particular, degradable starch microsphere trans-arterial chemo-embolization (DSM-TACE) combines the advantages of loco-regional approach (maximization of local drug delivering whilst reducing the systemic toxicity) with the ones of a resorbable carrier that significantly increases the safety profile of the procedure by reducing the ischaemia time and vessel occlusion rate [2] . A constraint of these treatments is the long period elapsed between the two cycles of administration and the post-procedural multidetector computed tomography (MDCT) reassessment. In fact, a patient with bilobar spread will complete treatment within 2 months (four cycles) and will be reassessed for lesion response with MDCT only after 1 month from the last DSM-TACE.
During the last few years, attention has been focused on the optimum modality for guidance of these treatments. The introduction of cone-beam computer tomography (CBCT) to the field of liver catheter-based procedures has contributed to significant improvement in clinical outcomes, versus the use of standard digital subtraction angiography (DSA) guidance alone [3] . In particular, CBCT has been able to depict a significant rate of occult lesions missed at pre-procedural MDCT [4] and the presence of extra-hepatic feeders [3, 5, 6] and provide a roadmap of the tumour vascular supply to facilitate successful and complete embolization [7] [8] [9] . Recently, dual-phase CBCT, consisting in introducing an additional delayed acquisition, has shown to facilitate hypovascular lesion visualization [10] .
Despite these advantages in aiding the embolization procedure, only a few studies have focused on this technique ability to intra-procedurally predict the treatment outcome, with controversial results [11, 12] . For these reasons the aim of this study is to evaluate the potential prognostic value of sequential dual-phase CBCT imaging performed during DSM-TACE session in predicting the nodule's response to treatment.
Materials and methods
This study was approved by the ethical institutional review board. Informed consent for the procedure for anonymized publication was obtained from all individual participants included in the study.
Between January and May 2018, 24 patients (mean age 68.5 ± 8.5 [45-85]) with HCC lesions (n = 96 [average 4 per patient]) were prospectively enrolled in the study. Imaging timing and embolization protocol were standardized. Inclusion criteria for treatment were established in consensus in a multidisciplinary board. All enrolled HCCs were of typical vascular behaviour (exhibiting washin in the arterial phase and washout on the delayed venous phase) diagnosed on the basis of MDCT only being greater than 2 cm in diameter. All patients were not eligible for either surgical or conventional catheter-based treatments (lipiodol or drug eluting beads TACE procedures) due to the total tumour burden. The patient's characteristics are summarized in Table 1 .
Multi-detector computed tomography (MDCT) technique
Multi-phasic CT was performed using a 64-slice MDCT scanner (Somatom Sensation 64; Siemens Medical Systems, Erlangen, Germany) with the following scan parameters: detector configuration 64 × 0.6; tube voltage 120 kVp; tube current 250 mAs; gantry rotation time: 0.33 s; pitch: 1; slice thickness: 3 mm.
All patients received 1.7 mL/kg bodyweight of Iomeprol-370 (Iomeron 370 ® ; Bracco Imaging, Milan, Italy), corresponding to 640 mg iodine/kg administered intravenously using a dual-chamber mechanical power injector (Stellant D CT; Medrad, Indianola, PA, USA) at a rate of 4.5 mL/s through an 18-gauge IV catheter inserted into an antecubital vein. Images of the liver were obtained during the late arterial, venous and delayed phases. The scan delay before the initiation of late arterial phase imaging was determined by means of bolus tracking with automated scan triggering (CARE Bolus CT; Siemens medical System). Arterial phase scanning began automatically 18 s after a trigger threshold 1 3 of 150 Hounsfield units (HU) was reached in the supraceliac abdominal aorta.
Dual-phase CBCT technique
All procedures were performed by the same interventional radiologist (BLIND, 10-year experience) in a dedicated angio-suite equipped with a ceiling-mounted angiographic C-arm system with 30 × 40 cm flat panel detector (Artis zee, Siemens Healthineers, Erlangen, Germany). Digital subtraction angiography (DSA) and CBCT were acquired after having positioned the 4-Fr catheter in the common hepatic artery coupled with a power injector (Mark V ProVis; Medrad, Beek, the Netherlands). Single-injection dual-phase CBCT was acquired, after having positioned the liver symmetrically in the isocentre of the C-arm rotation. Power injector parameters were 3.5 mL/s, 900 PSI, intra-arterial injection lasted 15 s and first CBCT acquisition started with 8-s delay from the injection start. These parameters were selected to allow liver parenchyma enhancement before first CBCT acquisition whilst maintaining arterial tree enhancement during the first CBCT acquisition. Delayed phase CBCT is acquired within 30 s from the first acquisition. Contrast media was diluted 2:3 with sterile saline to avoid streak artefacts. All intra-procedural CBCT acquisitions were performed with the same contrast media (Iomeron 370 ® ; Bracco Imaging, Milan, Italy). C-arm rotates 200° around the patient in 8-s acquiring images every 0.5° at 60 frame/second for a total of 419 images with a 512x512x387 matrix and isotropic resolution of 0.49 mm resulting in a 25 × 25 × 19 cm FOV. The data sets were automatically transferred to a workstation (X-Workplace, Siemens Healthineers, Erlangen, Germany) for reconstruction and analysis.
DSM-TACE protocol
The protocol stipulated two sessions of DSM-TACE on each involved lobe with 28 days between the two procedures. Patients with bilobar spread had each lobar treatment performed within 14 days of the other (see Fig. 1 ). Embolization was started with four millilitres of EmboCept ® S 50 μm microspheres (PharmaCept Gmbh, Berlin, Germany) loaded with Epirubicin (50 mg). Stasis of flow within the target artery was achieved with the remaining unloaded part of the EmboCept ® S vial (3.5 mL) or eventually with a second vial. All embolization procedures were performed via a coaxially positioned 2.7-Fr microcather (Progreat, Terumo, Tokyo, Japan). 
Imaging timing
Imaging assessment included a pre-procedural MDCT performed less than a month before treatment, a first dual-phase CBCT performed before the beginning of the first DSM-TACE session, a second dual-phase CBCT performed before the beginning of the second DSM-TACE session and a follow-up MDCT performed after 1 month after completion of treatment. In case of bilobar disease, a second cycle of treatment (2 DSM-TACE procedures) was performed with a scheduled shift of 14 days (see Fig. 1 ).
Analysis of lesion attenuation and pseudo-attenuation
Attenuation and pseudo-attenuation measurements were taken by measuring both pre-procedural and post-procedural MDCTs (arterial and venous phase acquisitions) and on all intra-procedural CBCT acquisition (arterial and venous acquisitions) forecast by the DSM-TACE protocol, respectively. Pseudo-attenuation, an arbitrary unit, that we will call HU* hereafter is related to the X-ray linear attenuation coefficient. Lesion attenuation and pseudo-attenuation were defined as the average HU/HU* value as measured on a manually drawn circular region of interest (ROIs) in order to encompass the whole lesion (intra-lesional necrosis or fatty degeneration areas were included in the ROI when present) (Fig. 2) . The measurements were repeated on the target axial image at all imaging time point. Attenuation values are expressed in Hounsfield unit (HU) for MDCT acquisitions, and pseudo-attenuation values are expressed in arbitrary unit in all intra-procedural CBCT acquisition.
To assess the predictive value of DP-CBCT regarding the DSM-TACE protocol per lesion, the modification over time of the lesion's attenuation was correlated with the post-procedural modify response evaluation criteria in solid tumours (mRECIST). In detail, the modification of pseudoattenuation and attenuation were calculated as the difference of: first CBCT and second CBCT values (arterial and venous acquisitions) and pre-procedural MDCT and post-procedural MDCT values (arterial and venous acquisitions).
Follow-up evaluation
Follow-up MDCT was performed to assess treatment outcome, according to mRECIST criteria [13] for HCC lesions. Response to treatment was categorized as: complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).
Statistical analysis
The normality of each continuous variable group was tested using the Kolmogorov-Smirnov Z test. Continuous data were described as the mean value ± SD, whereas non-Gaussian data were described as median and confidence interval 95%. Wilcoxon test was applied to verify the differences in attenuation between pre-and post-CBCT and CT (both arterial and venous phases). The Spearman and Pearson tests were used, according to data distribution, to verify the correlation with mRECIST criteria. (> 0.5 and < − 0.5 were considered as highly correlated/inversely correlated, respectively) The sample size analysis for receiver operating characteristics (ROC) was performed using: area under the curve (AUC) expected = 0.725 and the null hypothesis AUC = 0.5, α = 0.05, β = 0.20 with an expected ratio between 
Results
Twenty-four patients were enrolled in the study (20 were male [83.3%]). All patients had a multi-focal disease; among these, 7 (29.2%) were monolobar and 17 (70.8%) were bilobar (Table 1 ).
In total, 82 sessions of DSM-TACE were performed, respectively, two for each monolobar patients ( Except for first-second CBCT venous phase and second CBCT venous phase, the Kolmogorov-Smirnov Z test showed non-Gaussian distribution, and therefore, the respective parametric and nonparametric tests were applied. Lesion's attenuation values at pre-procedural MDCT were 107.00 HU (CI 95% 100.00-115.49) and 85.00 HU (CI 95% 81.13-91.74), respectively, in the arterial and venous phases. First CBCT arterial and venous pseudo-attenuation values were 305.00 HU* (CI 95% 259.77-354.04) and 155.00 HU* (CI 95% 135.00-163.34). Second CBCT arterial and venous pseudo-attenuation values were 210.00 HU* (CI 95% 179.47-228.58) and 141.00 HU* (CI 95% 125.47-158.11). Lesion's attenuation values at post-procedural MDCT were 95.00 HU (CI 95% 81.35-102.00) and 83.00 HU (CI 95% 78.00-88.00), respectively, in the arterial and venous phases. The complete data are listed in Table 2 .
For CR as outcome, a high inverse correlation was found for second MDCT arterial phase (− 0.56, p < 0.01). For OR, a high correlation was obtained for first-second CBCT arterial phase (0.53; p < 0.01).
The nodules sample size for ROC curve analysis demonstrated a need of 62 nodules for CR, 48 for OR and 68 for DC. ROC curve analysis (Fig. 3) showed that the higher the attenuation (HU and HU*) difference between pre-and postprocedural MDCT and first and second DP-CBCTs was, the better the clinical outcome will be. The most notable cut-off values for pre-post-MDCT arterial phase and first-second arterial phase DP-CBCT to predict CR, OR and DC were > 28 HU (sensitivity 86.7%, specificity 84.1%), > 18 HU (sensitivity 59.1%, specificity 88.7%), > − 4 HU (sensitivity 62.0%, specificity 84.6%) > 206 HU* (sensitivity 80.0%, specificity 81.71%), > 72 HU* (sensitivity 79.5%, specificity 83.0%) and > − 7 HU* (sensitivity 91.6%, specificity 65.4%), respectively. The complete analysis is shown in Table 3 and in Fig. 4 .
Discussion
A strong association was found between the change in lesion attenuation assessed intra-procedurally over a set of multiple DSM-TACE sessions and the prediction of treatment outcome evaluated at post-procedural MDCT. Patients demonstrating low lesion attenuation values after treatment (i.e. a high degree of tumour embolization) were more likely to experience response to treatment.
Recently, some preliminary attempts have been made to assess liver perfusion using CBCT imaging [12, 14, 15] . This technique requires the successive acquisition of a nonenhanced CBCT followed by a contrast enhanced one in the steady state of liver perfusion. By image normalization and subtraction, a software can calculate the blood volume in the liver parenchyma (PBV) of hypervascular lesions. Despite the advantages this technique could represent, it lacks the ability to characterize eventual occult/new lesions detected during the course of the treatment. Moreover, the lack of a delayed phase impedes washout depiction and thus intra-procedural lesion characterization. This point is crucial, especially when dealing with patients offered DSM-TACE protocol as supportive palliative care, as they usually suffer from advanced and aggressive disease. Vogl et al. [12] , despite failing to demonstrate a statistical significant association between initial blood volume and the response to TACE measured at MRI, demonstrate a trend of lower incidence of progressive disease in patients having higher preprocedural parenchymal blood volume (PBV). The importance of assessing the attenuation modification rather than simply assessing the baseline attenuation value is demonstrated by the study of Müller et al. [11] . They focused their studies on DP-CBCT imaging before single-session TACE procedures, failing to identify a statistically significant association (univariate and multivariate analysis) between lesion's attenuation and post-procedural mRECIST criteria. Attenuation modification evaluation could be of particular relevance even for patient with less advanced tumour burden. However, Loffroy et al. [16] , in a DEB-TACE study, in which single-step administration was performed, showed that the decrease in tumours' pseudo-attenuation between a pre-and post-procedural DP-CBCT strongly correlated with MR results (arterial r = 0.89 and venous r = 0.82 phases).
Our preliminary data show the DSM-TACE protocol could be tailored based on the pseudo-attenuation value of the second CBCT. In fact, no standard treatment scheme was defined in the literature regarding the eventual readministration of TACE (conventional TACE, DEB-TACE or DSM-TACE) protocol and several factors should be taken into account, including: procedure timeline and embolization drug choice [17, 18] . "On-demand" scheme, over the "scheduled one", is usually considered safer being re-treatment proposed only in case of progression of disease [19, 20] . In addition, no consensus has been present in the literature regarding which drug should be bounded to the embolization material in DSM-TACE [21] . However, Seki et al. [22] demonstrated that switching from epirubicin to cisplatin in patients with refractory response to epirubicin-loaded DEB-TACE is a safe, well-tolerated and efficacious treatment strategy. These inconclusive results could represent the bipolar aspects of HCC patients: the tumour burden and the underlining liver disease [19, 23] . However, unlike liver function, the effect of the DSM-TACE could be assessed only at the end of the pre-defined administrative protocol (2 sessions per lobe) by CT or MRI. Therefore, the possibility to predict intra-procedurally, with a predetermined cut-off, the effectiveness of the ongoing DSM-TACE treatment introduces another parameter that impacts the management of the patient, avoiding unnecessary drug administration that could potentially impair the limited liver functional reserve. For instance, the execution of DP-CBCT by demonstrating lesion attenuation modification by early prediction of treatment failure could permit either drug switch, drug combination or dosage adjustment. Our study presents several potential limitations. Firstly, sample size is small (24 patients), although the usage of a per-nodule analysis (96 nodules) in a subset of advanced disease patients supplies this limitation according to our sample size analysis. Secondly, because of the nature of the study no control group was taken into account. Thirdly, ours has a relative short-term follow-up (1 month). Fourthly, data did not derive from intra-procedural perfusion imaging but from multi-phasic one. Despite these limitations that can be addressed by increasing the sample size, we strongly believe that the lesion attenuation modification measurement is a simple tool that could lead to a significant clinical benefit.
Conclusion
DP-CBCT can predict intra-procedurally, by assessing lesion pseudo-attenuation modification, the DSM-TACE 1-month treatment outcome. Patients demonstrating high pseudoattenuation at the first arterial phase CBCT with a low lesion pseudo-attenuation in the second arterial phase CBCT values were more likely to experience response to treatment.
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